Clinical Trial Update: A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer. [Phase 2]

View source ↗

Summary

A Phase 2, single-arm, open-label trial examining surufatinib in combination with immunotherapy and chemotherapy for unresectable or metastatic biliary tract ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Surufatinib (Surufatinib)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Biliary Tract Cancer | Phase 2 | Status: NOT_YET_RECRUITING